CA9 and neoplasm: Although VEGF inhibitor increased tumor hypoxia in A549 and NCI-H1975 xenograft models, there are only 4 to 6% of total CA9+ cells that were CD47+, demonstrating that hypoxia was not the major cause of CD47 upregulation during anti-angiogenic therapy (Fig. 2a).